CJC-1295 + MOTS-c Stack: When to Pick One Over the Stack

What Each Peptide Is

CJC-1295 is a 29-amino-acid analogue of growth hormone-releasing hormone (GHRH) [1]. The DAC version carries an extra maleimidopropionic acid-lysine unit at its C-terminal end that lets it bind blood albumin and last much longer [1]. In the Teichman 2006 trials the estimated half-life after a single subcutaneous injection was 5.8 to 8.1 days [3]. It acts on the pituitary like GHRH to raise the body's own growth hormone (GH) and, through GH, IGF-I [3][8].

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA, first reported in 2015 by Lee et al. in Cell Metabolism [2][7]. In mouse and cell experiments its effects run through AMPK activation and inhibition of the folate cycle in skeletal muscle [7].

Is There Any Human Evidence for the Combination?

No. FDA found no study in which MOTS-c was given to a human, so no human study of the two together, or comparing one with the other, can exist [2].

CJC-1295's own base is thin. FDA identified three published human studies, all of the DAC form and all in healthy volunteers, with none in people who had a disease [1]. MOTS-c's position is weaker. FDA searched PubMed, Embase, the Cochrane library and other sources and found no clinical study in which MOTS-c was given to a human; the 12 papers a nominator cited were not clinical studies [2]. One laboratory observation adds a practical doubt: MOTS-c is quickly broken down in human blood in vitro, which raises the question whether an injection can produce active levels in a person at all [2].

When CJC-1295 Is the One With Data

If the question is GH and IGF-I, CJC-1295 is the only one of the pair with human measurements.

Teichman et al. ran two randomized, placebo-controlled, double-blind, ascending-dose trials lasting 28 and 49 days in healthy adults aged 21 to 61 [3]. After a single injection, mean plasma GH rose 2- to 10-fold for 6 days or more and mean IGF-I rose 1.5- to 3-fold for 9 to 11 days; after multiple doses, mean IGF-I stayed above baseline for up to 28 days [3]. No serious adverse reactions were reported [3]. Ionescu and Frohman gave healthy men aged 20 to 40 one injection of 60 or 90 micrograms/kg and sampled blood overnight a week later: GH pulse frequency and size were unchanged, trough GH rose about 7.5-fold, mean GH rose 46% and IGF-I 45% [8].

Doses in those studies were single subcutaneous injections of about 30 to 250 micrograms/kg, or two to three doses given weekly or every two weeks [1][3]. Those are study doses, not a recommended regimen, and there is no approved dose [1].

What the trials did not show is any health benefit. They measured hormone levels, not muscle, fat, sleep or lifespan, and ran for seven weeks at most [1][3]. FDA also noted that the human studies were short, small and mostly single-dose, so long-term safety is unknown [1]. No trial tested the form sold as CJC-1295 without DAC [1].

MOTS-c: Animal Data Only So Far

Every reported effect of administered MOTS-c comes from cells and rodents [2]. In mice, injected MOTS-c reduced weight gain on a high-fat diet (about 20% lower body weight after 8 weeks at 0.5 mg/kg/day intraperitoneal), improved insulin sensitivity and exercise performance, and a late-life schedule (15 mg/kg three times weekly from 23.5 months of age) lengthened median lifespan from 912 to 970 days [2][9]. FDA notes that its molecular targets are unknown and that no dose-response relationships were assessed [2]. In people, studies have only shown that exercise raises the body's own MOTS-c; nobody was given the peptide [9].

FDA's adverse-event database search through March 9, 2025 retrieved no MOTS-c reports, and FDA found no human exposure data by any route and no animal toxicity studies [2]. There are no pharmacokinetic data in humans or in live animals [2]. Rodent milligram-per-kilogram doses cannot be converted into a human dose [2]. FDA documents nominated 5 mg and 10 mg subcutaneous MOTS-c products, but no human dosing study has tested those amounts, so they are not recommended doses [2].

FDA's stated concern for injectable MOTS-c is immunogenicity, an immune reaction to peptide aggregates and impurities, and no immunogenicity data exist for this 16-amino-acid peptide [2].

Glucose: What Is Known for Each

FDA notes that GH and IGF-I elevation carries the risks listed on approved growth hormone labels, including glucose intolerance and diabetes [1]. MOTS-c's glucose effects are mouse data [7]. Because MOTS-c has not been given to people, there are no human data on whether it changes glucose handling, including in someone taking a GH-raising peptide.

Regulatory Status of Both

Neither is approved [1][2].

CJC-1295: on December 4, 2024, FDA's advisory committee voted 0 yes and 13 no on the free base, 1 yes and 12 no on the acetate, and 0 yes and 13 no on each of the three DAC forms, and FDA's reviewers proposed that none of the forms be added to the compounding bulks list [10]. The peptide now sits in the 'nominated but withdrawn' table on FDA's safety-risk page, having come off the category 2 list when nominators withdrew, and it is not in category 1 either [11][12]. It appears in none of the three categories of FDA's interim compounding policy and is not on the list for outsourcing facilities [12][13]. It is also not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [5].

MOTS-c: that draft policy does name MOTS-c, for the acetate form given by subcutaneous or intramuscular injection, and says HHS does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician that compounds it if the policy's conditions are met [6][5]. The notice states that it does not establish any rights for any person and is not binding on HHS or the public; it is a draft, not an approval and not a listing [6]. FDA staff recommended against adding MOTS-c to the bulks list, and the Pharmacy Compounding Advisory Committee voted in favor on July 23, 2026, which is advice only and not binding [2][14]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [6].

Sport: WADA names CJC-1295 in S2.2.4 as a growth hormone-releasing hormone analogue and MOTS-c in S4.4.1 as an AMPK activator; both are prohibited at all times, in and out of competition [4].

Choosing Between Them, on the Evidence

• The goal is GH and IGF-I. CJC-1295 is the only one of the two with human measurements of that effect, from three small, short studies in healthy volunteers; those studies measured hormone levels, not clinical outcomes [1][3].
• The goal is weight, glucose or mitochondrial function. MOTS-c has mouse data only, and FDA noted that approved treatments already exist for obesity and osteoporosis, two of the uses nominated for it [2].
• The goal is both. Each side would have to be justified on its own: GH and IGF-I measurements for CJC-1295, and mouse data for MOTS-c [1][2].

What the CJC-1295 Studies Reported

Per FDA's summary of the two Teichman trials: injection-site reactions in about 70% of treated subjects in study 1 and in all treated subjects in study 2; headache in 63% versus 14% on placebo in study 1; flushing, warmth and transient low blood pressure in about 30% of treated subjects in study 1; transient diarrhea; and transient dizziness and low blood pressure in two subjects [1][3]. Most events were more common at the higher doses of 125 or 250 micrograms/kg [1][3].

In the Ionescu and Frohman study, no serious adverse events occurred; dose-dependent increases in heart rate and transient injection-site redness and tenderness were reported [1].

FDA's stated concerns still posted for CJC-1295 include 'serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction', and it notes that available clinical data are limited [11]. FDA's briefing says ConjuChem withdrew CJC-1295 DAC from clinical trials in 2006 after a participant in a phase 2 trial in HIV lipodystrophy (192 enrolled) died. FDA cites news reports that the person had chest discomfort two hours after an 11th weekly dose and that the attending physician's most likely explanation was undiagnosed coronary artery disease with plaque rupture. The data were never published, so a causal link is neither shown nor excluded [1].